Patient Investing · Daily
Most coverage stops at the name: here is a good company, here is why it deserves a place in your portfolio. The harder half is the price. What is the market already paying for that quality, what has to be true for the number to make sense, and how much room is left if it is not.
One email before the opening bell, every weekday. Free, and simple to cancel.
General market commentary only — never personalized investment advice. We do not sell your address. Every issue carries an unsubscribe link.
The Three Questions
Three questions decide most of what happens afterwards. The rest is commentary around them.
Revenue durability, margin structure, capital intensity, and the debt maturity schedule — how the thing earns money when conditions are unfriendly, not when they are easy.
Multiples read against the company's own history and its closest peers, free cash flow relative to market value, and the growth rate already paid for at today's quote.
Where expectations sit, how crowded the view has become, and what conditions would make a holding worth starting, adding to, or simply leaving alone for now.
Inside Each Issue
Taken apart over a few hundred words rather than summarised in a headline.
Not "cheap" or "expensive" — which multiple, against which earnings, compared with what.
The growth and margin path required to justify it, so you can judge whether it is plausible.
The disconfirming case, written with the same care as the supporting one.
Often the business is fine and the price is not. That is a conclusion, and we print it.
If anyone connected to a company we mention paid us, it says so at the top.
Method
Annual report, segment detail, and the debt schedule — not a summary of them.
What the business earns on the capital it uses, and how stable that has been.
Compare what is being asked today with the company's own record and its peers.
Does this price allow for being wrong, or does it require everything to go right?
Editorial Position
We are not in a hurry. Activity feels like diligence, and most of what passes for investing is trading with a longer vocabulary. We publish every weekday because there is always something worth examining, not because there is always something worth doing. Plenty of issues end with the observation that the business has not changed and the price still asks too much.
We do not set price targets and we do not forecast the level of the index. Timing, in the sense we use it, means conditions rather than dates: what the market is currently assuming, how much of that assumption is already paid for, and what is left if it proves wrong. That question can be worked through. Naming the week a stock turns cannot.
We also do not promise outcomes. A careful process can look foolish for long stretches, and a reckless one can look brilliant for a while; both facts are ordinary features of markets rather than arguments about method. Any publication that resolves that tension for you is selling the resolution.
Free to join. One email each weekday morning, with a one-click exit in every one.